Collegium granted new patent

The patent contains claims that cover orally administrable compositions comprising Collegium’s proprietary micro-particle formulations. The formulations are designed to be more resistant to physical methods of tampering than currently available sustained release dosage forms. The patent is expected to provide protection for DETERx and products incorporating the DETERx technology into the year 2025.

The patent will provide broad coverage for Collegium’s abuse-deterrent, sustained-release, orally administered DETERx formulation platform. Collegium’s lead DETERx product candidate, COL-003, a formulation of sustained release oxycodone, will also be covered by the patent.

The DETERx platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper resistant properties, the multi-particulate design potentially allows patients with difficulty swallowing to open the capsule and administer the contents on food or with water, while maintaining the sustained release properties of the product.

Michael Heffernan, president and CEO of Collegium, said: “This patent will protect a variety of active ingredients incorporated into DETERx, in addition to our lead product COL-003. We intend to continue to prosecute additional patents that will strengthen our intellectual property for this technology.”